All information on this website is intended strictly for educational and research purposes only.
The content on OpenPep — including peptide profiles, clinical trial summaries, dosing information, and reconstitution calculators — must not be used for:
OpenPep aggregates publicly available clinical trial data and research. We do not sell, distribute, or recommend any substances. All AI-generated summaries are interpretations of published research and may contain errors.
Survodutide (GLP-1/Glucagon dual agonist)
For educational and research purposes only. Not medical advice.
Survodutide shows up to 19% weight loss in Phase II and exceptional liver fat reduction (up to 87% in MASH patients). The glucagon component differentiates it from pure GLP-1 agonists by directly targeting hepatic fat metabolism.
Best Time
Any time, same day each week
Method
subcutaneous
Frequency
Once weekly
Half-life
~5-6 days
Cycle Length
Ongoing (clinical trial)
Storage
Refrigerate at 2-8°C.
Published Dosing Ranges
Create an account to access peptide research data.
Contraindications
Create an account to access peptide research data.
Endocrinology, diabetes & metabolism 9 (2) :e70187 · 2026-03-01
Obesity (Silver Spring, Md.) 33 (11) :2046-2054 · 2025-11-01
The Journal of clinical endocrinology and metabolism 110 (10) :2964-2979 · 2025-09-16
Diabetes, obesity & metabolism 27 (12) :7062-7074 · 2025-12-01
Alimentary pharmacology & therapeutics 61 (12) :1872-1888 · 2025-06-01
Mechanism of Action
Dual agonist of GLP-1 and glucagon receptors. Combines appetite suppression (GLP-1) with enhanced energy expenditure and hepatic fat reduction (glucagon).
Reported by the community. These may not be supported by clinical evidence and are not medical recommendations.